Alvotech (NASDAQ:ALVO) Upgraded by Zacks Research to Hold Rating

Alvotech (NASDAQ:ALVO) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Morgan Stanley set a $10.00 price target on Alvotech in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research note on Wednesday, January 21st. Barclays began coverage on shares of Alvotech in a research report on Monday, December 8th. They set an “underweight” rating and a $5.00 target price for the company. Finally, Wall Street Zen downgraded shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Alvotech has an average rating of “Hold” and a consensus target price of $8.60.

Alvotech Stock Performance

Shares of NASDAQ ALVO opened at $3.53 on Thursday. The firm has a 50 day moving average price of $4.53 and a two-hundred day moving average price of $5.87. The stock has a market cap of $1.06 billion, a P/E ratio of 35.30 and a beta of 0.16. Alvotech has a 52-week low of $3.42 and a 52-week high of $11.85.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%.The business had revenue of $173.20 million for the quarter, compared to analyst estimates of $162.20 million. Analysts predict that Alvotech will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ALVO. Invesco Ltd. lifted its holdings in shares of Alvotech by 57.5% in the 4th quarter. Invesco Ltd. now owns 73,360 shares of the company’s stock worth $376,000 after purchasing an additional 26,784 shares in the last quarter. Millennium Management LLC increased its stake in Alvotech by 1,707.7% during the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after purchasing an additional 337,417 shares in the last quarter. Stifel Financial Corp acquired a new position in Alvotech during the fourth quarter worth $108,000. Jane Street Group LLC acquired a new position in Alvotech during the fourth quarter worth $474,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after buying an additional 122,089 shares in the last quarter.

Alvotech News Summary

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Q4 and FY‑2025 revenue beat and bullish 2026 outlook — Q4 revenue was $173M (+13% YoY) and FY revenue was $593M (+21% YoY); management reiterated 2026 revenue guidance of $650–700M and raised adjusted EBITDA guidance. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Positive Sentiment: Regulatory approvals, commercial launches and partner deals expand near‑term commercial runway — multiple biosimilars (e.g., AVT05, AVT03) cleared in Europe/UK, a marketing application accepted for AVT23, U.S. launch activity via partners (Selarsdi™), and supply/commercialization agreements with Sandoz for key territories. Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments
• Positive Sentiment: Balance sheet and leadership moves reduce execution risk — Alvotech raised ~\$300M, listed on Nasdaq Stockholm, expanded R&D via acquisitions, and appointed Lisa Graver as CEO and other senior hires to support scaling. Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO
• Neutral Sentiment: U.S. approvals expected late‑2026 but management says they will have minimal 2026 topline impact — this tempers upside from potential FDA wins this year. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage and price‑target dispersion — several buy/overweight ratings and median analyst target near \$9 show upside in some forecasts, but targets vary widely—expect mixed analyst reactions. Alvotech Reports Q4 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Short‑interest data reported for March appears inconsistent/invalid (entries show 0 shares and NaN increases), so short‑interest signals are currently unreliable. (Multiple short‑interest notices 3/18–3/20)
• Negative Sentiment: EPS missed consensus — reported EPS of $0.03 vs. consensus ~$0.13, which can pressure sentiment despite the revenue beat. Alvotech earnings summary
• Negative Sentiment: FDA inspection observations remain an overhang — management says improvements are underway and resubmissions are planned for Q2 2026, but regulatory risk could delay U.S. commercialization and investor confidence. Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).